{
  "metadata": {
    "case_id": 73,
    "model": "Gemini-3-Pro",
    "timestamp": "2025-11-29T18:28:49.549605",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/73_NCT03228836.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Gemini-3-Pro/73_Gemini-3-Pro.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.94
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.94,
          "status": "matched",
          "ref_item": {
            "label": "Sintilimab (IBI308)",
            "type": "EXPERIMENTAL",
            "interventionNames": [
              "Drug: Sintilimab"
            ]
          },
          "pred_item": {
            "label": "Sintilimab",
            "type": "EXPERIMENTAL",
            "description": "Patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL) who failed to at least one asparaginase-based regimen were enrolled to receive sintilimab.",
            "interventionNames": [
              "Sintilimab"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.98
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Sintilimab",
            "description": "Sintilimab (IBI308) 200mg IV Q3W",
            "armGroupLabels": [
              "Sintilimab (IBI308)"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "Sintilimab",
            "description": "Sintilimab 200 mg administered intravenously every 3 weeks until progressive disease, death, intolerable toxicity, or withdrawal of informed consent, up to 24 months.",
            "armGroupLabels": [
              "Sintilimab"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.88
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.88,
          "status": "matched",
          "ref_item": {
            "measure": "Objective Response Rate (ORR) Before First PD",
            "description": "The tumor assessment is according to Lugano 2014 Criteria and then International Working Group (IWG) 2007 Criteria after 24 weeks. Objective response is defined as best overall response (CR or PR) across all assessment time points during the period from enrollment to termination of trial treatment (per Lugano 2014 criteria during intial 24 weeks, per IWG 2007 criteria after 24 weeks). The primary efficacy endpoint is ORR evaluated using the 2014 Lugano Criteria before first progression disease (PD).",
            "timeFrame": "Up to ~30 months (through database cut-off date of 28-February-2020)"
          },
          "pred_item": {
            "measure": "Objective Response Rate (ORR)",
            "description": "Defined as the percentage of patients achieving a Complete Response (CR) or Partial Response (PR) based on Lugano 2014 criteria.",
            "timeFrame": "Up to 24 months"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 8,
      "similarity_matrix": [
        [
          0.3,
          0.25,
          0.3,
          0.32,
          0.6,
          0.4,
          0.1,
          0.12
        ],
        [
          0.4,
          0.32,
          0.5,
          0.4,
          0.97,
          0.2,
          0.11,
          0.05
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 5,
          "score": 0.4,
          "status": "matched",
          "ref_item": {
            "measure": "Progression Free Survival (PFS)",
            "description": "PFS was defined as the time from the first dose to the first documented progressive disease (PD) per Lugano 2014 or death due to any cause, whichever occurred first. Participates who neither progress nor die were censored at the date of their last tumor imaging evaluation. Participates who did not have any tumor imaging evaluation after baseline were censored on the date of enrollment.",
            "timeFrame": "Up to ~30 months (through database cut-off date of 28-February-2020)"
          },
          "pred_item": {
            "measure": "1-year Overall Survival (OS)",
            "description": "Proportion of patients alive at 1 year; overall survival was defined as the time from enrollment to death from any cause.",
            "timeFrame": "Up to approximately 30 months"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 4,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Duration of Response (DOR)",
            "description": "DOR was defined as the time from first date of response to first PD per Lugano 2014 or death. Subjects who neither progress nor die were censored at the date of their last tumor imaging evaluation.",
            "timeFrame": "Up to ~30 months (through database cut-off date of 28-February-2020)"
          },
          "pred_item": {
            "measure": "Duration of Response (DOR)",
            "description": "Time from the first documented response to disease progression or death.",
            "timeFrame": "Up to approximately 30 months"
          }
        }
      ]
    }
  ]
}